Results 1 to 5 of 5
Page 1 of 1
TypeTitleAuthor(s)YearViews
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B
Journal:
Gut
Publisher:
BMJ Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
Lai, CL; Ahn, SH; Lee, KS; Um, SH; Cho, M; Yoon, SK; Lee, JW; Park, NH; Kweon, YO; Sohn, JH; Lee, J; Kim, JA; Han, KH; Yuen, RMF201383
 
Week 48 analysis of a Phase IIB study of the efficacy and safety of LB80380 vs. entecavir in treatment-naive patients with chronic Hepatitis B
Proceedings/Conference:
Hepatology
Publisher:
John Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Lai, CL; Ahh, SH; Lee, KS; Um, SH; Cho, M; Yoon, SK; Lee, JW; Park, NH; Kweon, YO; Sohn, JH; Lee, J; Kim, JA; Han, KH; Yuen, MF2011152
 
A phase IIb study of the efficacy and safety of LB80380 vs entecavir in treatment-naive patients with chronic hepatitis B
Proceedings/Conference:
Hepatology
Publisher:
Elsevier BV.
Lai, CL; Ahn, SH; Lee, KS; Um, SH; Cho, M; Yoon, SK; Lee, JW; Park, NW; Kwon, YO; Sohn, JH; Lee, JY; Park, HE; Kim, JA; Han, KH; Yuen, MF2011270
 
Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease
Journal:
Hepatology
Publisher:
John Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Yuen, MF; Han, KH; Um, SH; Yoon, SK; Kim, HR; Kim, J; Kim, CR; Lai, CL2010136
 
Phase II multi-centre, dose-escalating study of LB80380 (ANA380) in hepatitis B patients with lamivudine-resistant YMDD mutant HBV
Proceedings/Conference:
Journal of Hepatology
Publisher:
Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Lai, CL; Han, KH; Yoon, SK; Um, SH; Yuen, MF; Kim, HS; Kim, HR; Chung, HC; Kim, CR; Hsyu, P; Averett, D; Worland, S; Kim, J2006254
 
Page 1 of 1
Export Records
Step 1: Select content and export format
  • Citation only
Step 2: Select export method
  • Download